Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Clinical Trials

Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans

Early Phase 1

Completed

Conditions: Sleep Wake Disorders
Sleep Deprivation
Sleep

Interventions: Drug: Carvedilol 25mg
Drug: Placebo oral capsule

First Posted Date: 2018-07-03

Last Posted Date: 2022-11-23

Lead Sponsor: Gitte Moos Knudsen

Target Recruit Count: 22

Registration Number: NCT03576664

Locations: 🇩🇰
Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark

Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.

Phase 3

Conditions: Chemotherapy Related Cardiac Dysfunction

Interventions: Drug: Carvedilol

First Posted Date: 2018-05-31

Last Posted Date: 2018-05-31

Lead Sponsor: Makerere University

Target Recruit Count: 50

Registration Number: NCT03542058

Carvedilol in Treating Hypoglycemia Unawareness

Phase 2

Terminated

Conditions: Hypoglycemia Unawareness

Interventions: Drug: Carvedilol 2.5 mg
Drug: Carvedilol 3.125 mg
Drug: Placebo capsule

First Posted Date: 2018-05-25

Last Posted Date: 2020-11-25

Lead Sponsor: Owen Chan, PhD

Target Recruit Count: 1

Registration Number: NCT03538015

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Phase 3

Recruiting

Conditions: Stage IV Breast Cancer AJCC v6 and v7
Recurrent Breast Carcinoma
HER2/Neu Positive
Metastatic Malignant Neoplasm in the Brain
Cardiotoxicity

Interventions: Other: Laboratory Biomarker Analysis
Drug: Carvedilol
Other: Patient Observation

First Posted Date: 2018-02-01

Last Posted Date: 2025-05-15

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 817

Registration Number: NCT03418961

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States

and more 587 locations

Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
Adverse Effect of Beta-adrenoreceptor Antagonists
Asthma

Interventions: Drug: Metoprolol succinate ER
Drug: Carvedilol

First Posted Date: 2017-12-12

Last Posted Date: 2017-12-12

Lead Sponsor: VA Greater Los Angeles Healthcare System

Target Recruit Count: 21

Registration Number: NCT03370835

Locations: 🇺🇸
VA West Los Angeles Medical Center, Los Angeles, California, United States

Immediate Release Versus Slow Release Carvedilol in Heart Failure

Phase 4

Conditions: Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Carvedilol IR (Immediate Release)
Drug: CarVeDilol-SR (Slow Release)

First Posted Date: 2017-07-06

Last Posted Date: 2017-07-06

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 320

Registration Number: NCT03209180

Locations: 🇰🇷
Korea Univ. Guro Hospital, Seoul, Guro, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Il-won, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Songpa, Korea, Republic of

and more 10 locations

WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis

Conditions: Cirrhosis
Portal Hypertension

Interventions: Drug: Carvedilol

First Posted Date: 2017-06-22

Last Posted Date: 2017-06-22

Lead Sponsor: Shanghai Changzheng Hospital

Target Recruit Count: 80

Registration Number: NCT03195634

Can MRI Evaluate Beta-blocker Response in Portal Hypertension?

Conditions: Liver Cirrhosis
Portal Hypertension
Varix, Esophageal

Interventions: Drug: Carvedilol
Other: MRI scan
Procedure: Hepatic Venous Pressure Gradient (HVPG)

First Posted Date: 2017-04-14

Last Posted Date: 2018-05-08

Lead Sponsor: University of Nottingham

Target Recruit Count: 68

Registration Number: NCT03114813

Locations: 🇬🇧
NIHR Nottingham Biomedical Research Centre, Nottingham, Nottinghamshire, United Kingdom
🇬🇧
University of Nottingham, Nottingham, United Kingdom